Treats poisoning. Sold as Atnaa, Duodote. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Atropine; Pralidoxime Chloride (sold as Atnaa, Duodote), first approved Jan 17, 2002, with 1 new use approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Magnesium Sulphate With Atropine and Pralidoxime vs Standard Therapy Alone in Acute Organophosphate PoisoningOrganophosphate Poisoning · Muhammad Aamir Latif | Not applicable | Recruiting | Aug 20, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA